The antiinfective medicine market in Sweden has seen diverse fluctuations over the past decade. Between 2013 and 2023, the market experienced peak sales in 2018, followed by dips and recoveries. The value stood at 4.07 billion Swedish Kronas in 2023, marking a 14.77% year-on-year increase. Despite this recovery, the overall trend had notable downturns, affecting the CAGR, which was -2.17% for the recent 5-year period.
From 2024 onwards, forecasts suggest a moderate yet steady rise. By 2028, the market is expected to reach 4.58 billion SEK, driven by a forecasted 5-year CAGR of 1.89%, indicating a 9.79% growth rate over the five years.
Future Trends to Watch For:
- Increased investment in R&D and innovative antiinfective treatments.
- Potential shifts in population health dynamics and disease prevalence.
- Impact of healthcare policies and funding on medicine accessibility.
